.................................................................................................................................................................................................................................................................................................
.
.

Only 22 percent of clinical trials actually finish on time

Delays in clinical trials can mean a loss in potential revenue, but most importantly, a lost chance to be the first to offer an improved standard of care to patients in need.

With SpineMark's award-winning suite of solutions, we can quickly navigate your product's path to market. Plus, our top-performing research sites are ready to start enrolling patients for your study.

Based on its combined leadership -- Co-Medical Directors, Hansen Yuan, MD and Gunnar Andersson, MD, Director of Research, Steve Garfin, MD, and our Medical Advisory Board-SpineMark CRO Management is a world-class leader in all aspects of medical device research.